SynthesisBMC neurology2026
Neutrophil to high-density lipoprotein cholesterol ratio and prognosis in acute ischemic stroke: a systematic review and meta-analysis.
Synthesis in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe neutrophil to high-density lipoprotein cholesterol ratio (NHR) is emerging as a potential composite biomarker integrating aspects of inflammation and lipid metabolism in the context of acute ischemic stroke (AIS). However, its clinical utility remains uncertain due to limited and inconsistent evidence across studies.
methodsA comprehensive systematic search was conducted in PubMed, Embase, and the Cochrane Library up to September 2025 to identify studies examining the association between NHR and adverse outcomes or mortality in AIS patients. Heterogeneity among studies was evaluated through sensitivity and subgroup analyses, and potential publication bias was explored using Egger's test, recognizing the limited power due to the small number of included studies.
resultsA meta-analysis including 4,138 patients from five studies suggested a possible association between higher NHR and adverse outcomes in AIS (OR 1.89, 95% CI: 1.18-3.02; I² = 82%), although substantial heterogeneity limits confidence in the pooled estimate. Sensitivity analyses yielded similar trends, but findings should be interpreted cautiously. Subgroup analyses indicated stronger associations for patients undergoing reperfusion therapy (OR 2.80, 95% CI: 1.79-4.38) and at 3-month follow-ups (OR 2.24, 95% CI: 1.51-3.32), while no significant associations were observed with conventional treatment or 1-month follow-ups. The pooled area under the curve (AUC) was 0.63, reflecting limited predictive performance. Only a single study examined mortality, reporting no significant association with NHR (OR 1.5; 95% CI: 0.47-4.74).
conclusionsElevated NHR is associated with adverse outcomes in AIS, supporting its potential as a prognostic biomarker. However, evidence for mortality prediction is limited, and further prospective studies are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.